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Abstract. 
Background: The frequency of pain and cramps is uncertain in anti-MAG (Anti-myelin associated 
glycoprotein antibody) neuropathy. Whether these symptoms may affect function/quality of life is 
unknown.  
Methods: We performed a cross-sectional study of the prevalence, correlates and impact of pain, pain 
subtypes and cramps, their severity, frequency and anatomical distribution, in 55 clinically stable 
patients with anti-MAG neuropathy.  
Results: Pain of any type was reported by 80% of subjects. The most common subtype was 
paraesthesiae and dysaesthesiae (70%). Cramps were reported by >60% of patients, with lower limb 
cramps in all and upper limb cramps, in about 20%. Cramps affected daily activities in >30% of these 
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subjects, sleep in 60%, ability to exercise in >30%. Total Pain Score correlated with several SF-36 
health-related quality of life (SF-36 HR-QoL) measures (p<0.05), with Inflammatory Rasch-Built 
Overall Disability Scale (I-RODS) (p=0.006) and 10-metre timed walk (p=0.019). An independent 
association was ascertained with I-RODS (p=0.002). Different pain subtypes showed multiple 
associations with SF-36 HRQoL measures and/or functional scales. Upper limb cramps had multiple 
SF-36 HRQoL/functional correlates, with an independent association with the Overall Neuropathy 
Limitation Score (ONLS) (p=0.004). Cramp severity correlated with ONLS (p=0.04) and I-RODS 
(p=0.028) and inversely with level of physiotherapy input (p=0.009). Cramp frequency was associated 
with tremor score (p=0.004) and multiple SF-36 HRQoL subsections.  
Conclusions: Neuropathic pain and cramps may affect function and quality of life in anti-MAG 
neuropathy. Optimizing treatments of these symptoms, including by adequate levels of physiotherapy, 
may be beneficial in affected patients and requires further research.  
 
Introduction. 
Anti-myelin associated glycoprotein antibody (Anti-MAG) neuropathy is a paraproteinaemic 
demyelinating neuropathy of usually slow progression resulting in disability through distal sensory 
more than motor deficits, as well as tremor. Neuropathic pain and cramps can be prominent and 
disabling [1-4]. We have previously described our findings of a study on the functional determinants 
of quality of life in this multicentre cohort [5]. This current analysis focused on the issue of pain and 
cramps in patients with anti-MAG neuropathy. 
 
There are currently no effective, evidence-based immunotherapy treatments for anti-MAG neuropathy 
[6]. Immunoglobulins may have some short-term effect [6] but their appropriateness in this setting is 
highly questionable. In addition, following unconvincing initial results of a randomized controlled 
trial of Rituximab which had suggested a possible, albeit moderate, beneficial effect [7], a subsequent 
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larger trial showed globally negative results [8]. Globally, a recent meta-analysis provides however 
globally, low-quality evidence for Rituximab and further longer-duration trials are needed [6]. 
Consideration of potential determinants of disability and quality of life is important in this medically 
currently untreatable disorder as may help shed light on potentially useful symptomatic therapies and 
ways of improving patients’ daily lives.  
 
The main objective of the current analysis was to evaluate the impact pain and its severity and quality, 
as well as of cramps, their severity, frequency and anatomical location, on neurological function and 
quality of life in patients with anti-MAG neuropathy.  
Patients and Methods. 
We performed a cross-sectional study of patients with a clinically, electrophysiologically and 
immunologically confirmed diagnosis of anti-MAG neuropathy, attending our respective 
neuromuscular clinics for their routine follow-up assessments, between March 2015 and February 
2016. Inclusion criteria were (i) mainly distal sensory-predominant neuropathy (ii) presence of an 
IgM monoclonal protein (iii) presence of anti-MAG antibodies >1500 BTU [9] (iv) distal predominant 
demyelinating physiology (v) clinically stable for 3 months at time of assessment. Patients were 
evaluated irrespective of previous immunomodulatory therapies received and of current or previous 
treatments for pain and cramps.   
 
Pain was evaluated by a validated Pain Questionnaire, the NPSI (Neuropathic Pain Symptom 
Inventory) [10]. The questionnaire is detailed in its English language version, in Table 1 (Online 
Supplementary Material). The Total Pain Score was the sum of the intensity scores for the different 
pain subtypes. We also established, for each subject, [10], pain sub-scores.  
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Cramps were evaluated by a validated questionnaire [11]. This questionnaire is detailed in its English 
language version in Table 2. (Online Supplementary Material) and ascertained severity, frequency 
and precise anatomical location of cramps.  
 
All participants received a clinical assessment as part of their routine evaluation with: 80-point 
Medical Research Council (MRC) sum scores, Inflammatory Neuropathy Cause and Treatment 
(INCAT) Sensory Sum Score (INCATSSS) [12], Jamar grip dynamometry for dominant and non-
dominant hands, Overall Neuropathy Limitation Score (ONLS) [13], Inflammatory Rasch-built Overall 
Disability Score (I-RODS) [14], 10-metre timed walk, ataxia score [8], Whiget tremor score [15]. 
Health-related Quality of Life (HR-QoL) was ascertained by an interviewer-administered SF-36 
Questionnaire [16] and fatigue by the Fatigue Severity Scale (FSS) [17]. Social support was 
determined by a modified abbreviated version of the Medical Outcome Study-Social Support Survey 
(MOSS) [18].  Level of physiotherapy input determined by a questionnaire, based on current 
recommendations for access to therapy in the U.K. [19].  This is detailed in Table 3 (Online 
Supplementary Material).  
No further evaluations were performed. Patients did not undergo any additional electrophysiological 
tests, further blood tests, imaging or cerebrospinal fluid examinations for the current analysis. 
Biological and electrophysiological data were obtained from available records.  
 
The SF-36 HRQoL Questionnaire was individually categorized before data analysis, as previously 
established, in different domains, consisting of “Physical Function” (PF), “Role Physical (RP), “Bodily 
Pain” (BP), “General Health” (GH), “Vitality” (VT), “Social Functioning” (SF), “Role Emotional” (RE), 
“Mental Health”, “Physical Component Score” (PCS) and “Mental Component Score” (MCS). Inter-
correlations were ascertained and independent associations were sought. 
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This work was approved and registered by our relevant respective institutional review boards. All 
patients provided informed written consent. Statistical analyses were performed using SPSS 23.0 
software (SPSS Inc., Chicago, IL, USA). Correlations were determined by using Spearman’s 2-tailed 
correlation. As this study was exploratory, correction for multiple testing was not performed. 
Multivariate logistic regression was used to determine eventual independent associations. P values 
<0.05 were considered as significant.  
 
Results. 
We recruited 55 patients (32 from Marseille, France, 7 from Angers, France, and 16 from 
Birmingham, U.K.). There were 38 males and 17 females. Mean age was 71.5 years (S.D.: 10.3). Mean 
disease duration was 7.4 years (S.D.: 5.9). Mean anti-MAG antibody titer was 43813 BTU (S.D.: 
26827.5). 
There were no significant differences between the French and U.K. cohorts in terms of general 
prevalence and/or severity of pain (p=0.55), and cramps (p=0.54), gender distribution (p=0.14), age 
(p=0.62) or disease duration (p=0.23). All physical assessments, including MRC sum score (p=0.87), 
Jamar grip dynamometry (p=0.54), ONLS (p=0.11), I-RODS (p=0.66), INCATSSS (p=0.60), 10-meter 
timed walk (p=0.46), ataxia score (p=0.65), tremor score (p=0.25), Fatigue Severity Score (p=0.86), 
were comparable in the French and U.K. cohorts.  
 
Prevalence of evaluated symptoms are described in Table A. Most patients had a chronic sensory 
neuropathy with sensory ataxia (34/55, 62%) and upper limb tremor (27/55, 49%).  Pain of any type 
was described by 44/55 patients (80%). Burning superficial spontaneous pain was reported by 21/55 
(38.2%), pressing deep spontaneous pain by 19/55 (34.5%), paroxysmal pain by 27/55 (49.1%), 
evoked pain by 28/55 (50.1%) and paraesthesiae/dysaesthesiae by 39/55 (70.1%). Cramps were 
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reported by 35/55 (63.6%). Upper limb cramps were present in only 10 of these 35 patients with 
cramps (28.6%) whereas lower limb cramps were described by all 35. Cramps affected daily activities 
in 11/35 (31.4%) of these subjects, sleep in 21/35 (60%), ability to exercise in 11/35 (31.4%) and the 
patient perception of quality of life in 12/35 (34.3%). 
Main results of correlation analyses showed multiple positive associations of pain severity and 
quality of life and disability. These are detailed in Table B.  
Total Pain Score correlated with several SF-36 HR-QoL measures (p<0.05) (see Table B.), with I-RODS 
(p=0.006) and 10-metre timed walk (p=0.019). The Total Pain Score was independently associated 
with BP (p<0.001). Considering only the functional parameters, an independent association was 
found with the I-RODS (p=0.002).  
Burning superficial spontaneous pain was independently associated with the INCATSSS (p=0.004) 
and modified MOSS (p=0.008).  
Paroxysmal pain was independently associated with PCS (p=0.007). Amongst the functional 
parameters, an independent association was found with ataxia score (p=0.007).  
Paraesthesiae/dysaesthesiae were independently associated with BP (p=0.004). Considering non-HR-
QoL parameters, an independent association was found with mean FSS (p=0.029). 
 
Main correlation results of the cramp characteristics are summarized in Table C. Again, multiple 
positive associations were ascertained between cramp location, severity and frequency and quality 
of life and function. Lower limb cramps correlated with ataxia score only, amongst all studied 
functional parameters (p=0.034). 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Upper limb cramps were independently associated with PF (p=0.011). An independent association 
was found with the ONLS (p=0.004). More precise cramp location was relevant to performance and 
function as hand cramps were independently associated with ONLS (p=0.015). Cramp frequency was 
independently associated with RE (p=0.031) and BP (p=0.031).  
 
Patients describing interference of cramps with their daily activities were significantly more likely to 
have a lower MRCSS (p=0.045), worse arm ONLS score (p=0.003) and total ONLS score (p=0.009), 
lower I-RODS (p=0.035), higher INCATSSS (p=0.038) and higher tremor score (p=0.027). Patients who 
felt cramps interfered with their ability to exercise were more likely to have lower arm ONLS scores 
(p=0.016). Those who described a perceived impact of their cramps on their global quality of life 
were similarly more likely to have lower ONLS arm scores (p=0.018), but also more severe ataxia 
(p=0.031), although SF-36 parameters failed to be influenced.  
 
The level of physiotherapy input correlated with the Total Pain Score (p=0.024). Also, level of 
physiotherapy input was associated the presence of cramps (p=0.04). However, conversely and 
remarkably, cramp severity was strongly inversely associated with the level of physiotherapy input 
(p=0.009). Similarly, an independent negative association was found between level of physiotherapy 
input and cramps interfering with sleep (p=0.011). 
The level of social support (modified MOSS) was associated with the presence of burning pain 
(p=0.024), but not with any other pain or cramp characteristics or features. 
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Discussion. 
Our multicentre analysis of 55 patients firstly indicates that both pain and cramps are common 
features that may significantly impact upon HR-QoL, as well on function in patients with anti-MAG 
neuropathy. Importantly, both may be more frequent with longer disease duration, indicating the 
importance and relevance of regular re-assessments. 
The frequency of pain was high, occurring in 80% of our cohort. Paraesthesiae and dysaesthesiae, 
although often considered as non-painful symptoms by patients and physicians, were present in 
>70%. Consideration of pain management, appears therefore highly relevant in anti-MAG 
neuropathy, as has been found previously in relation to quality of life more generally in neuropathy 
[20]. Similarly, we found comparable findings about cramps in our cohort. Although cramps were 
reported by 63.6% of patients, they affected mostly the lower limbs, with <20% describing upper 
limb involvement. Hand cramps appeared however the most relevant to disability with an 
independent association with the ONLS. Interestingly, whereas cramp severity was associated with 
neurological disability, cramp frequency on the other hand was related to HR-QoL measures, with 
independent associations with RE and BP. This is in keeping with previous findings in genetic 
neuropathy [11].  
We found that presence of cramps was associated with higher levels of physiotherapy input. This 
may be intuitively expected as probably relates to the naturally higher likelihood of referrals of more 
affected subjects. However, the concomitant finding of worst cramps in patients with the lowest 
physiotherapy input may suggest a favorable effect of physiotherapy on cramp severity. We in 
addition, found that cramps interfering with sleep also inversely correlated with level of 
physiotherapy. This is in keeping with some recent literature [21], although the benefit of non-
medical interventions for cramps is, to our knowledge, not established from meta-analyses 
performed to date [22].  
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HR-QoL measures represent the markers that ultimately need to be positively influenced by 
treatment interventions for meaningful benefit to patients [23]. Pain can be a prominent although 
under-recognized feature of inflammatory neuropathy [24, 25], and anti-MAG neuropathy may be a 
likelier cause of pain amongst immune-mediated neuropathies [24]. In that study, positive sensory 
symptoms of paraesthesiae and dysesthesiae were commonest. Our current results appear 
confirmatory of these findings and in agreement with the conclusions of that previous study that 
these are symptoms often not considered as pain in the clinical setting.  
We did not evaluate the effects of previous immunotherapy or of medical treatments for pain and 
cramps in our cohort. This was because our aim was to cross-sectionally ascertain occurrence and 
correlates of these symptoms rather than retrospectively attempt to determine drug effects. We 
otherwise did not here specifically consider co-morbidities which may have resulted in arthritic or 
musculo-skeletal pains and this represents a limitation of our study. 
Only properly designed therapeutic drug trials may in future answer the question regarding the 
eventual efficacy of pain and cramp treatment on function and quality of life in anti-MAG 
neuropathy. The benefits of physiotherapy input optimization are possible, this despite the cross-
sectional and non-controlled nature of our analysis. The scale we used to determine level of 
physiotherapy input is clearly limited as does not consider intensity of sessions or differences of 
practice between physiotherapists and institutions, which limits the value of the findings. However, 
benefit of physiotherapy in anti-MAG neuropathy may merit further study in the setting of an 
adequate randomized controlled interventional trial. As demonstrated in other neuromuscular 
disorders, favorable effects of non-drug interventions such as aerobic exercise training and cognitive 
behavioral therapy may be obtained and objectively measurable [26].  
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In conclusion, we believe our study brings new insight on practical management of patients with 
anti-MAG neuropathy, in indicating that pain and cramp severity, frequency, quality and distribution 
can play a significant part in the impairment of function and quality of life in affected patients. This is 
important in a disorder for which effective evidence-based treatments remain unavailable. Future 
research may need to focus on these associated secondary, to date still poorly-recognized symptoms 
of anti-MAG neuropathy, both in terms of therapeutic benefit of evaluated drugs and other 
interventions, as well as, eventually, consideration of these manifestations per se, as primary 
therapeutic targets. 
Table A. Prevalence of evaluated symptoms in 55 patients with anti-MAG neuropathy. 
 
 
 
 
 
 
 
 
 
 
 
Table B. Correlates of Pain (Total Pain 
Symptom Prevalence in 
cohort 
Percentage 
Sensory Ataxia 34/55 62% 
Upper Limb Tremor 27/55 49.1% 
Pain of any type 44/55 80% 
Burning superficial 
spontaneous pain 
19/55 34.5% 
Paroxysmal pain 27/55 49.1% 
Evoked pain 28/55 50.1% 
Paraesthesiae, 
Dysaesthesiae 
39/55 70.1% 
Cramps 35/55 63.6% 
Upper Limb cramps 10/55 18.2% 
Lower Limb cramps 35/55 63.6% 
Cramps affecting 
daily activities 
11/55 20% 
Cramps affecting 
sleep 
21/55 38.2% 
Cramps affecting 
ability to exercise 
11/55 20% 
Cramps affecting 
patient perception of 
quality of life 
12/55 21.8% 
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Score and Pain Quality) with functional and Health-Related Quality of Life Parameters in 55 
patients with anti-MAG neuropathy. 
 
 
NPSI Total Pain 
Score 
Burning Pain Pressing  Pain 
Paroxysmal 
Pain 
Paraesthesiae/ 
Dysaethesiae 
Disease. 
duration 
NS 
Rho:0.438 
P=0.047 
NS NS NS 
MRC sum 
score 
NS NS NS NS NS 
Dominant 
Grip 
NS NS NS NS NS 
ONLS Total NS NS NS 
Rho:0.527; 
P=0.005 
NS 
I-RODS 
Rho=-0.409; 
P=0.006 
NS NS 
Rho:-0.435; 
P=0.023 
Rho:-0.313; 
P=0.049 
INCAT 
sensory sum 
score 
NS 
Rho: 0.469 
P=0.037 
NS 
Rho:0.447; 
P=0.025 
NS 
Ataxia score NS NS NS 
Rho:0.461; 
P=0.015 
NS 
Whiget 
Tremor 
score 
NS NS NS NS NS 
Ten meter 
walk 
Rho:0.425; 
P=0.019 
NS NS 
Rho:0.755; 
P<0.001 
NS 
Modified 
MOSS 
NS 
Rho: 0.491; 
P=0.024 
NS NS NS 
Fatigue 
Severity 
Scale (mean 
score) 
Rho: 0.360; 
P=0.018 
NS 
Rho:0.467; 
P=0.044 
Rho:0.444; 
P=0.020 
Rho:0.376; 
P=0.017 
PF NS NS NS 
Rho:-0.417; 
P=0.03 
NS 
RP NS NS NS NS NS 
BP 
Rho:-0.661; 
P<0.001 
NS 
Rho:-0.678; 
P=0.001 
NS 
Rho:-0.454; 
P=0.003 
GH 
Rho=-0.366 
P=0.014 
NS NS 
Rho:-0.386; 
P=0.047 
Rho:-405; 
P=0.010 
VT 
Rho=-0.307; 
P=0.043 
NS NS NS NS 
SF NS NS NS NS NS 
RE NS NS NS NS NS 
MH 
Rho=-0.316 
P=0.037 
NS NS NS 
Rho:-0.391; 
P=0.013 
PCS 
Rho=-0.432; 
P=0.003 
NS NS 
Rho:-0.520; 
P=0.005 
NS 
MCS NS NS NS NS NS 
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Table C. Correlates of various cramp characteristics with functional and Health-Related Quality of 
Life Parameters in 55 patients with anti-MAG neuropathy. 
 
 
Presence of 
Cramps 
Cramp 
Frequency 
(number of 
days or nights 
per week) 
Severity 
Of Worst 
Cramp 
 
 
Hand 
Cramps  
Cramps 
Interfering 
With  
Daily 
Activities 
Cramps 
Interferin
g with 
Sleep 
 
Cramps 
Interfering 
with 
Quality of 
Life 
Disease. 
duration 
Rho:0.289 
P=0.034 
NS NS 
Rho: 
0.367 
P=0.030 
 
 
NS 
NS NS 
MRC sum score NS NS NS 
Rho=-0.439 
P=0.008 
Rho=-0.41 
P=0.045 
NS NS 
Dominant Grip NS NS NS 
Rho= 
-0.447; 
P=0.015 
NS 
NS NS 
ONLS Total NS NS 
Rho=-0.360 
P=0.004 
Rho:0.46 
P=0.005 
Rho:-0.433 
P=0.009 
NS NS 
I-RODS NS NS 
Rho=0.383 
P=0.028 
Rho: 
0.371 
P=0.028 
Rho:-0.357 
P=0.035 NS NS 
INCAT sensory 
sum score 
NS NS NS 
 
NS 
Rho:0.369 
P=0.038 
NS NS 
Ataxia score 
Rho: 0.305 
P=0.028 
NS NS 
Rho: 
0.398 
P=0.022 
NS 
NS 
Rho:0.376 
    P=0.031 
Whiget Tremor 
score 
NS 
Rho:0.418; 
P=0.024 
NS 
 
NS 
Rho:0.386 
P=0.027 
NS NS 
Ten meter 
walk 
NS NS NS 
 
NS 
NS 
NS NS 
Modified 
MOSS 
NS NS NS 
 
NS 
NS 
NS NS 
Level of 
Physiotherapy 
Input 
Rho:0.28 
P=0.040 
NS 
Rho=-0.449 
P=0.009 
 
NS 
 
NS 
Rho: 
-0423 
NS 
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P=0.011 
Fatigue 
Severity Scale 
(mean score) 
NS 
Rho:0.472 
P=0.007 
NS 
 
NS 
 
NS 
NS NS 
PF NS NS NS NS 
Rh:-0.457 
P=0.006 
NS NS 
RP NS 
Rho:-0.55 
P=0.001 
NS NS 
Rh:-0.4 
P=0.017 
NS NS 
BP NS 
Rho:-0.405 
P=0.024 
NS NS 
NS 
NS NS 
GH NS NS NS NS 
Rh:-0.353 
P=0.038 
NS NS 
VT NS 
Rho:-0.453 
P=0.011 
NS NS 
Rho:-0.372 
P=0.038 
NS NS 
SF NS 
Rho:-0.614 
P<0.001 
 
NS NS 
Rho:-0.486 
P=0.003 NS 
Rho:-0.374 
P=0.027 
RE NS 
Rho:-0.590 
P=0.001 
NS NS 
NS 
NS NS 
MH NS 
Rho:-0.511 
P=0.003 
NS NS 
NS 
NS NS 
PCS NS NS NS NS 
Rho:-0.566 
P<0.001 
NS NS 
MCS NS 
Rho:-0.564 
P=0.001 
NS NS 
NS 
NS NS 
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